Navigation Links
Run for Your Life
Date:8/11/2008

Exercisers live longer and with fewer disabilities, study finds

MONDAY, Aug. 11 (HealthDay News) -- It may, in fact, be possible to outrun death -- and even the creeping ravages of time -- at least for a while.

Research spanning two decades has found that older runners live longer and suffer fewer disabilities than healthy non-runners.

And the findings probably apply to a variety of aerobic exercises, including walking, said the study authors, from Stanford University School of Medicine, whose findings are published in the Aug. 11 issue of the Archives of Internal Medicine.

"This is telling you that being a runner, being active is going to reduce your disability, and it's going to increase your survival," said Marcia Ory, professor of social and behavioral health at the Texas A&M Health Science Center College of Rural Public Health in College Station. "Late in life, you still see the benefit of vigorous activity."

In 1980, the study's lead author, Dr. James Fries, emeritus professor of medicine at Stanford, wrote a landmark paper outlining his "compression of morbidity" hypothesis. The theory held that regular exercise would compress, or reduce, the amount of time near the end of life when a person was disabled or unable to carry out the activities of daily living, such as walking, dressing and getting out of a chair.

"Illness would be compressed between later age of onset and age of death, and that paradigm was controversial, because it went against conventional wisdom and had no proof," Fries explained.

At the time, many experts believed that vigorous exercise would actually harm older individuals. And running, in particular, would result in an epidemic of joint and bone injuries.

But this new study proves otherwise.

Two hundred and eighty-four runners and 156 healthy "controls," or non-runners, in California completed annual questionnaires over a
'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved

Page: 1 2 3

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)... , Brain perfusion applic...nterprise using the Ziostation® thin-client sy...if (PRWEB) January 8, 2009 -- Ziosoft®, Inc. ...software for medical imaging , today announced th...Food and Drug Administration (FDA) for its CT brai...
(Date:1/7/2009)... , SEATTLE, Jan. 8 Ce... announced today that they received $7.5 million p...trum Pharmaceuticals, Inc. to commercialize and de..., the Company received the initial $7.5 million pa...action. The Company may earn up to an additional ...
(Date:1/7/2009)... , BOSTON The drive toward containing health ca...reducing physician productivity, impairing quality...l Deaconess Medical Center physicians suggest in a..., Citing studies in behavioral economics and psyc...D, express the fear that assigning a monetary valu...
(Date:1/7/2009)... , SAN MARCOS, Calif., Jan, 7 Natural Alternative... leading formulator, manufacturer and marketer of ...d that effective December 31, 2008 its former Pres... , , NAI also announced it completed certain amen...k. Among other changes the amendments extend the ...
Breaking Medicine News(10 mins):Health News:Ziosoft Receives FDA Clearance for CT Brain Perfusion Application 2Health News:Cell Therapeutics Receives $7.5 Million Under Joint Venture Agreement With Spectrum Pharmaceuticals 2Health News:Cell Therapeutics Receives $7.5 Million Under Joint Venture Agreement With Spectrum Pharmaceuticals 3Health News:Cell Therapeutics Receives $7.5 Million Under Joint Venture Agreement With Spectrum Pharmaceuticals 4Health News:Cost containment focus could have consequences for health care delivery 2Health News:Natural Alternatives International, Inc. Announces Change in Executive Officer and Loan Modification and Extension 2
...high cholesterol levels are more likely to develop.... Researchers studied the eating habits and choles...about five years. The children were examined by do...ol, and LDL, or bad cholesterol, measured periodic...
...e that male babies who grow slowly in their first ... results hold true regardless of the socioeconomic...w infant growth may be accompanied by hampered bra...oor growth in infancy lead to lifelong impairment ...
...solved the puzzle of why baby boys are so much big...ring pregnancy. Women carrying male embryos consum...re protein and have a higher intake of carbohydrat...cepted that on average newborn boys are heavier th...
... the frequency of hot flashes in menopausal women,...gh an independent researcher said the drug's effec...rmone replacement therapy for menopausal symptoms ...sleep problems will be looked at more closely beca...
Other Medicine News:
(Date:1/6/2009)...RNewswire/ -- Pacira Pharmaceuticals, Inc., an,ac...ed today that enrollment,has been completed in tw...,safety and efficacy of a single intraoperative ad... prolonged postoperative analgesia. , Resul...al knee,arthroplasty (TKA) are expected to provid...
(Date:1/3/2009)...EMONT, Ill., Jan. 2 Mag...ogy providing an increasing number of clinical ben...ording to an article in the January 2009 issue of ... Surgeons ( http://www.jaaos.org/ ). It is predic...echnical developments will allow MRI to provide ev...
(Date:12/27/2008)...ar silence, offers to ease cloning costs for Clona...Dec. 27 Six years to th...d child, Dr. Brigitte Boisselier, head of the comp...ther babies cloned by her company are growing up h... families, privacy. , , "We,ve helped almost 10...
(Date:12/17/2008)...FirstCall/ -- Medivation, Inc.,(Nasdaq: MDVN ) ...llment in a,Phase 1-2 dose-escalation clinical tr...onist, in castration-resistant prostate cancer pat...S. Food and Drug Administration (FDA) to,advance ... open-label, U.S. Phase 1-2 study evaluated prosta...
Breaking Medicine Technology:Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment 2Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment 3MRI Emerges As Vital Resource in Treatment of Back Pain 2MRI Emerges As Vital Resource in Treatment of Back Pain 3'We're Ready to Prove It!' 2Medivation Completes Enrollment of Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients 2Medivation Completes Enrollment of Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients 3Medivation Completes Enrollment of Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients 4Cardica to Announce Fiscal 2008 Fourth Quarter and Year End Financial Results on Tuesday August 5 2008 24489 1Cardica to Announce Fiscal 2008 Fourth Quarter and Year End Financial Results on Tuesday August 5 2008 24489 2DoctorDirectory to Co market VoSpire ER 28R 29 with DAVA Pharmaceuticals Inc 24486 1DoctorDirectory to Co market VoSpire ER 28R 29 with DAVA Pharmaceuticals Inc 24486 2InfoLogix Selected by University Medical Center to Deploy Mobile Wireless Asset Tracking Solution 24483 1InfoLogix Selected by University Medical Center to Deploy Mobile Wireless Asset Tracking Solution 24483 2InfoLogix Selected by University Medical Center to Deploy Mobile Wireless Asset Tracking Solution 24483 3Poniard Pharmaceuticals Announces Upcoming Conference Participation 6783 1Poniard Pharmaceuticals Announces Upcoming Conference Participation 6783 2
...., May 09, 2007 /PRNewswire-FirstCall/ --,Catalyst...itive,initial, top-line results from a bioequivale...igabatrin Tablets) is bioavailable and,bioequivale...rketed,in Europe by Sanofi Aventis. These data pot...e extensive body of published pre-clinical,and cli...
...if.--(BUSINESS WIRE)--May 10, 2007 - According to,...65 percent of,female respondents seeking treatment...Painkillers such as Vicodin, OxyContin, Percocet,a...n, 35 percent of,the mothers who reported a depend... to Clare Waismann, registered addiction,specialis...
Other Medicine Technology:Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results,of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Company's,Investigational Drug to Treat Cocaine and Methamphetamine Addiction 2Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results,of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Company's,Investigational Drug to Treat Cocaine and Methamphetamine Addiction 3Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results,of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Company's,Investigational Drug to Treat Cocaine and Methamphetamine Addiction 4Waismann Method Survey Reveals 65 Percent of Women Seeking Opiate,Dependency Treatment Are Mothers 2
Pneumatic impactor, general surgery, available in various hose connector styles.
The SmartDriver System consists of a pistol-grip handpiece available in Pneumatic, Electric and Battery Power, with a wide range of couplers that can be used in a variety of orthopedic surgical appli
Introducing the new large power line from MicroAire. Our new handpieces function as both cordless AND electric instruments, offering the ultimate in flexibility. Its the versatility the industry has
The 7600 Oscillating Saw offers unparalleled power for large bone osteotomies, thanks to its 14.4V NiMH Rechargeable Battery Pack. The cutting head may be rotated into 12 positions for cutting in any
Medicine Products: